Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.

Libbrecht E, Doutreloigne J, Van De Velde H, Yuen MF, Lai CL, Shapiro F, Sablon E.

J Clin Microbiol. 2007 Dec;45(12):3935-41. Epub 2007 Oct 3.

3.

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.

Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E.

J Clin Microbiol. 2002 Oct;40(10):3729-34.

4.

[YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].

Arslan U, Ural O, Findik D.

Mikrobiyol Bul. 2008 Jul;42(3):445-50. Turkish.

PMID:
18822888
5.

[Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year].

Aydoğan S, Ergünay K, Balaban Y, Alp A, Simşek H, Tatar G, Hasçelik G, Us D.

Mikrobiyol Bul. 2013 Jul;47(3):472-81. Turkish.

6.

Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients.

Mese S, Arikan M, Cakiris A, Abaci N, Gumus E, Kursun O, Onel D, Ustek D, Kaymakoglu S, Badur S, Yenen OS, Bozkaya E.

J Gen Virol. 2013 Dec;94(Pt 12):2729-38. doi: 10.1099/vir.0.053041-0. Epub 2013 Sep 17.

PMID:
24045109
7.

Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.

Chen CH, Lee CM, Tung WC, Wang JH, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS.

J Hepatol. 2010 Apr;52(4):478-85. doi: 10.1016/j.jhep.2010.01.006. Epub 2010 Feb 2.

PMID:
20185198
9.

In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.

Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.

Antivir Ther. 2004 Jun;9(3):353-63.

PMID:
15259898
10.

Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.

Chang UI, Lee YC, Wie SH, Jang JW, Bae SH, Choi JY, Yang JM, Yoon SK, Sun HS.

J Med Virol. 2007 Jul;79(7):902-10.

PMID:
17516533
11.

Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.

Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.

J Med Virol. 2007 Nov;79(11):1664-70.

PMID:
17854034
12.

Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.

Zaaijer HL, Takkenberg RB, Weegink CJ, Rebers SP, Menting S, Reesink HW, Schinkel J, Molenkamp R.

J Med Virol. 2009 Mar;81(3):413-6. doi: 10.1002/jmv.21401.

PMID:
19152408
13.

[Determination of hepatitis B virus genotype and detection of lamivudine-resistance mutations].

Nogales MC, Serrano MC, Suárez E, Corpas R, Pérez L, Claro R, Jarana R, Romero-Gómez M, Martín-Mazuelos E.

Gastroenterol Hepatol. 2004 Nov;27(9):515-20. Spanish.

PMID:
15544736
14.

YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.

Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH.

J Gastroenterol Hepatol. 2006 Dec;21(12):1783-8.

PMID:
17074014
15.

Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.

Cha CK, Kwon HC, Cheong JY, Cho SW, Hong SP, Kim SO, Yoo WD.

J Med Virol. 2009 Mar;81(3):417-24. doi: 10.1002/jmv.21402.

PMID:
19152409
16.

Monitoring of therapy in patients with chronic hepatitis B virus.

Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R.

Eur J Gastroenterol Hepatol. 2010 Jun;22(6):736-40. doi: 10.1097/MEG.0b013e32832e0a44.

PMID:
19550344
17.

Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.

Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H.

J Med Virol. 2011 Jun;83(6):953-61. doi: 10.1002/jmv.22025.

PMID:
21503906
18.

[A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations].

Ağca H, Sayıner AA, Sengönül A, Simşek I, Akarsu M.

Mikrobiyol Bul. 2011 Oct;45(4):664-76. Turkish.

PMID:
22090297
19.

Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort.

Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, Brinkman K, Meenhorst PL, de Man RA.

J Clin Virol. 2002 Apr;24(3):173-81.

PMID:
11856618
20.

Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.

Inoue J, Ueno Y, Wakui Y, Niitsuma H, Fukushima K, Yamagiwa Y, Shiina M, Kondo Y, Kakazu E, Tamai K, Obara N, Iwasaki T, Shimosegawa T.

J Viral Hepat. 2011 Mar;18(3):206-15. doi: 10.1111/j.1365-2893.2010.01301.x.

PMID:
20367795

Supplemental Content

Support Center